Brief: Cidara Therapeutics Q2 Operating Expenses USD 27.384 Million

Cidara Therapeutics

07/08/2025 21:05

Overview

Cidara Q2 net loss narrows to $25.7 mln from $91.2 mln in 2024

Co raises $402.5 mln in public offering, strengthening balance sheet

Result Drivers

PHASE 2B SUCCESS - CD388 met all primary and secondary efficacy endpoints in Phase 2b NAVIGATE trial, showing strong protection against influenza

FINANCIAL STRENGTH - $402.5 mln raised in public offering to support Phase 3 development of CD388

FDA ENGAGEMENT - End of Phase 2 meeting request submitted to FDA to discuss Phase 3 study design

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$1.65
Q2 Net Income
-$25.72 mln
Q2 Operating Expenses
$27.38 mln
Q2 Operating Income
-$27.38 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cidara Therapeutics Inc is $56.50, about 9.7% below its August 6 closing price of $61.99

Press Release: ID:nGNX3SFNy7

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)